Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

APLMBearishCorporate Developmentsnews

High materiality8/10

Apollomics faces Nasdaq MVLS delisting risk; Asia rights for APL-101 regained

Jun 24, 2026, 4:21 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Near-term delisting risk can erode liquidity and investor confidence; however, regained Asia rights and consolidated global control could offset some downside if it leads to profitable deals. Similar past cases show stock price undershoots when MVLS issues persist, with limited immediate upside until compliance is restored.

AI summary

What happened, with direct paths to the underlying reporting

Apollomics disclosed a Nasdaq notice for MVLS non-compliance, granting a 180-day window to restore a $35 million market value by December 15, 2026. Separately, the company terminated its Launxp license due to nonpayment, pursuing recovery and dispute resolution, while reclaiming Asia rights to APL-101 and consolidating global rights outside China and Macau, potentially enabling broader partnerships and faster development.

Nasdaq MVLS below $35M triggers 180-day cure period; Dec 15, 2026 deadline.
Delisting risk remains if MVLS not restored; current trading continues.
Launxp breach ends collaboration; Apollomics to recover $3.8M and breach remedies.
Asia rights to APL-101 revert to Apollomics; global rights consolidated (US/Europe/APAC).
APL-101 remains a Phase 2 c-Met inhibitor; strategic focus shifts to partnerships.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.